1. The Emerging Role of Cytidine Deaminase in Human Diseases: A New Opportunity for Therapy?
- Author
-
Audrey Frances, Pierre Cordelier, Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and CCSD, Accord Elsevier
- Subjects
Genetic Structures ,[SDV]Life Sciences [q-bio] ,Review ,03 medical and health sciences ,chemistry.chemical_compound ,Structure-Activity Relationship ,0302 clinical medicine ,Cytidine Deaminase ,Drug Discovery ,Genetics ,Medicine ,Animals ,Humans ,Bloom syndrome ,Genetic Predisposition to Disease ,Molecular Biology ,030304 developmental biology ,Pharmacology ,Regulation of gene expression ,0303 health sciences ,business.industry ,Cancer ,Cytidine ,Cytidine deaminase ,Genetic Therapy ,medicine.disease ,Gemcitabine ,3. Good health ,[SDV] Life Sciences [q-bio] ,chemistry ,Gene Expression Regulation ,Genetic Loci ,030220 oncology & carcinogenesis ,Cancer research ,Molecular Medicine ,Deoxycytidine ,Disease Susceptibility ,business ,DNA ,medicine.drug - Abstract
International audience; The recycling activity of cytidine deaminase (CDA) within the pyrimidine salvage pathway is essential to DNA and RNA synthesis. As such, CDA deficiency can lead to replicative stress, notably in Bloom syndrome. Alternatively, CDA also can deaminate cytidine and deoxycytidine analog-based therapies, such as gemcitabine. Thus, CDA overexpression is often associated with lower systemic, chemotherapy-related, adverse effects but also with resistance to treatment. Considering the increasing interest of CDA in cancer chemoresistance, the aims of this review are to describe CDA structure, regulation of expression, and activity, and to report the therapeutic strategies based on CDA expression that recently emerged for tumor treatment.
- Published
- 2019